Galapagos NV: business update: http://t.co/6w1jppWE
posted 4 days ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
Pharmaneuroboost (PNB) reported today that it will present, on August 31st, new study results on dose-related 5HT2A receptor occupancy of pipamperone at the 23th Annual Meeting of the European College of Neuropsychopharmacology (ECNP) in Amsterdam.
“Our new data confirm that low dose pipamperone provides adequate 5HT2A binding in humans without clinically relevant D2 binding at doses that were shown to enhance the antidepressant effect of citalopram in depressed patients”, says Chief Executive Officer Erik Buntinx, psychiatrist, who was first to identify and report the beneficial clinical effects of PNB01 in patients.
“The data also provide support for a once daily dosing regimen for PNB01”, continues Erik Buntinx, “and will guide us in selecting the most appropriate dose(s) of pipamperone to be tested in further clinical studies to come”. PNB01 is a proprietary owned, fixed dose combination of citalopram and low dose pipamperone, and is under development for the treatment of Major Depressive Disorder.
PharmaNeuroBoost NV, founded in 2006, is a biopharmaceutical company located in Belgium, dedicated to developing best in class CNS therapeutics, based on solid intellectual property. The company’s primary goal is to significantly improve current therapy targeted against mood, anxiety, and psychotic disorders. The two front-running clinical stage proprietary projects (PNB01 and PNB02) are targeted against major depression and schizophrenia, respectively.
Source: PharmraNeuroBoost
Tags: clinical trials
Bookmark this:
